ArticleBritish journal of cancer2004

Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy.

A Gennari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.